In a groundbreaking achievement for both diabetes care and Mercy’s commitment to innovative patient solutions, we are excited to announce that Mercy successfully placed the world’s first patient with the Eversense® 365 Continuous Glucose Monitor (CGM) on Oct. 10 at Mercy St. Louis. 

Meet Chris Walker, 56, a type 2 diabetic who has battled his blood sugar for years and struggles to keep it under control. On Oct. 10, he became the world’s first patient to have the Eversense 365 continuous glucose monitor placed. Walker, a patient of Dr. Ray Weick, was referred to Dr. Jake Goldstein who placed the device.

This marks the global debut of the only FDA-approved, year-long implantable CGM system. This milestone represents a significant step forward in how we care for patients with diabetes, offering them a more convenient, effective way to monitor blood glucose levels—without the frequent sensor replacements typical of other CGM systems.

The Eversense 365 system, which has been FDA-approved for use in adults with Type 1 and Type 2 diabetes, allows continuous glucose monitoring for a full 365 days in comparison to traditional monitors which only last 10-14 days. 

After initial calibration, the Eversense 365 system only requires weekly blood sugar testing for continued calibration.